Clinical-grade multipotent adult progenitor cells durably control pathogenic T cell responses in human models of transplantation and autoimmunity

Journal of Immunology

Volumn 190, Issue 9, 2013, Pages 4542-4552

  Reading, James L ^a   Yang, Jennie H M ^a   Sabbah, Shereen ^a   Skowera, Ania ^a   Knight, Robin R ^a   Pinxteren, Jef ^b   Vaes, Bart ^b   Allsopp, Timothy ^c   Ting, Anthony E ^d   Busch, Sarah ^d   Raber, Amy ^d   Deans, Robert ^d   Tree, Timothy I M ^a,e  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b ReGenesys   (Belgium)

^c PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^d ATHERSYS INC   (United States)

^e GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 17; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ALLOTRANSPLANTATION; ARTICLE; AUTOIMMUNE DISEASE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; FLOW CYTOMETRY; GRAFT REJECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOPATHOLOGY; IN VITRO STUDY; LYMPHOCYTE FUNCTION; MALE; MESENCHYMAL STEM CELL; MULTIPOTENT STEM CELL; PANCREAS ISLET CELL; PANCREAS ISLET TRANSPLANTATION; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SUPPRESSOR CELL; T LYMPHOCYTE; TH1 CELL; TH17 CELL;

ADULT; ADULT STEM CELLS; AUTOIMMUNITY; CELL PROLIFERATION; CELLS, CULTURED; DIABETES MELLITUS, TYPE 1; GRAFT REJECTION; HUMANS; IMMUNOMODULATION; INTERLEUKIN-10; ISLETS OF LANGERHANS TRANSPLANTATION; LYMPHOCYTE ACTIVATION; MALE; STEM CELLS; T-LYMPHOCYTES, REGULATORY; TH1 CELLS; TH17 CELLS; TRYPTOPHAN; YOUNG ADULT;

EID: 84876797993     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1202710     Document Type: Article

References (55)

1. English, K., and B. P. Mahon. 2011. Allogeneic mesenchymal stem cells: agents of immune modulation. J. Cell. Biochem. 112: 1963-1968.
2. Salem, H. K., and C. Thiemermann. 2010. Mesenchymal stromal cells: current understanding and clinical status. Stem Cells 28: 585-596.
3. Le Blanc, K., and D. Mougiakakos. 2012. Multipotent mesenchymal stromal cells and the innate immune system. Nat. Rev. Immunol. 12: 383-396.
4. Dominici, M., K. Le Blanc, I. Mueller, I. Slaper-Cortenbach, F. Marini, D. Krause, R. Deans, A. Keating, Dj. Prockop, and E. Horwitz. 2006. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 8: 315-317. (Pubitemid 44269669)
5. Sohni, A., and C. M. Verfaillie. 2011. Multipotent adult progenitor cells. Best Pract. Res. Clin. Haematol. 24: 3-11.
6. Jacobs, S. A, V. D. Roobrouck, C. M. Verfaillie, and S. W. Van Gool. 2013. Immunological characteristics of human mesenchymal stem cells and multi-potent adult progenitor cells. Immunol. Cell Biol. 91: 32-39.
7. Boozer, S., N. Lehman, U. Lakshmipathy, B. Love, A. Raber, A. Maitra, R. Deans, M. S. Rao, and A. E. Ting. 2009. Global Characterization and Genomic Stability of Human MultiStem, A Multipotent Adult Progenitor Cell. J. Stem Cells 4: 17-28.
8. Kovacsovics-Bankowski, M., K. Mauch, A. Raber, P. R. Streeter, R. J. Deans, R. T. Maziarz, and W. Van't Hof. 2008. Preclinical safety testing supporting clinical use of allogeneic multipotent adult progenitor cells. Cytotherapy 10: 730-742.
9. Abdallah, B. M., M. Haack-Sørensen, J. S. Burns, B. Elsnab, F. Jakob, P. Hokland, and M. Kassem. 2005. Maintenance of differentiation potential of human bone marrow mesenchymal stem cells immortalized by human telo-merase reverse transcriptase gene despite [corrected] extensive proliferation. Biochem. Biophys. Res. Commun. 326: 527-538. (Pubitemid 39642757)
10. Vaes, B., W. Van't Hof, R. Deans, and J. Pinxteren. 2012. Application of MultiStem(®) Allogeneic Cells for Immunomodulatory Therapy: Clinical Progress and Pre-Clinical Challenges in Prophylaxis for Graft Versus Host Disease. Front. Immunol. 3: 345.
11. Medicetty, S., D. Wiktor, N. Lehman, A. Raber, Z. B. Popovic, R. Deans, A. E. Ting, and M. S. Penn. 2012. Percutaneous adventitial delivery of allogeneic bone marrow-derived stem cells via infarct-related artery improves long-term ventricular function in acute myocardial infarction. Cell Transplant. 21: 1109-1120.
12. Reading, J. L., S. Sabbah, S. Busch, and T. I. Tree. 2013. Mesenchymal stromal cells as a means of controlling pathological T-cell responses in allogeneic islet transplantation. Curr. Opin. Organ Transplant. 18: 59-64.
13. Skowera, A., M. Hotopf, E. Sawicka, R. Varela-Calvino, C. Unwin, V Nikolaou, L. Hull, K. Ismail, A. S. David, S. C. Wessely, and M. Peakman. 2004. Cellular immune activation in Gulf War veterans. J. Clin. Immunol. 24: 66-73. (Pubitemid 38375797)
14. Arif, S., T I. Tree, T. P. Astill, J. M. Tremble, A. J. Bishop, C. M. Dayan, B. O. Roep, and M. Peakman. 2004. Autoreactive T cell responses show proinflammatory polarization in diabetes but a regulatory phenotype in health. J. Clin. Invest. 113: 451-463. (Pubitemid 38544189)
15. Skowera, A., R. J. Ellis, R. Varela-Calvino, S. Arif, G. C. Huang, C. Van-Krinks, A. Zaremba, C. Rackham, J. S. Allen, T. I. Tree, et al. 2008. CTLs are targeted to kill beta cells in patients with type 1 diabetes through recognition of a glucose-regulated preproinsulin epitope. [Published erratum appears in 2009 J. Clin. Invest. 119: 2844.] J. Clin. Invest. 118: 3390-3402.
16. Blomberg, K., R. Hautala, J. Lövgren, V M. Mukkala, C. Lindqvist, and K. Akerman. 1996. Time-resolved fluorometric assay for natural killer activity using target cells labelled with a fluorescence enhancing ligand. J. Immunol. Methods 193: 199-206. (Pubitemid 26227987)
17. Knight, R. R., D. Kronenberg, M. Zhao, G C. Huang, M. Eichmann, A. Bulek, L. Wooldridge, D. K. Cole, A. K. Sewell, M. Peakman, and A. Skowera. 2013. Human b-cell killing by autoreactive preproinsulin-specific CD8 T cells is predominantly granule-mediated with the potency dependent upon T-cell receptor avidity. Diabetes 62: 205-213.
18. Roep, B. O., I. Stobbe, G Duinkerken, J. J. van Rood, A Lernmark, B. Keymeulen, D. Pipeleers, F. H. Claas, and R. R. de Vries. 1999. Auto-and alloimmune reactivity to human islet allografts transplanted into type 1 diabetic patients. Diabetes 48: 484-490. (Pubitemid 29106860)
19. Arif, S., F Moore, K. Marks, T. Bouckenooghe, C. M. Dayan, R. Planas, M. Vives-Pi, J. Powrie, T. Tree, P. Marchetti, et al. 2011. Peripheral and islet interleukin-17 pathway activation characterizes human autoimmune diabetes and promotes cytokine-mediated b-cell death. Diabetes 60: 2112-2119.
20. Tree, T. I., J. Lawson, H. Edwards, A. Skowera, S. Arif, B. O. Roep, and M. Peakman. 2010. Naturally arising human CD4 T-cells that recognize islet autoantigens and secrete interleukin-10 regulate proinflammatory T-cell responses via linked suppression. Diabetes 59: 1451-1460.
21. van den Boogaardt, D. E., P. P. van Miert, Y. J. de Vaal, J. W. de Fijter, F. H. Claas, and D. L. Roelen. 2006. The ratio of interferon-gamma and interleukin-10 producing donor-specific cells as an in vitro monitoring tool for renal transplant patients. Transplantation 82: 844-848. (Pubitemid 44470389)
22. Zelenika, D., E. Adams, S. Humm, C. Y. Lin, H. Waldmann, and S. P. Cobbold. 2001. The role of CD4+ T-cell subsets in determining transplantation rejection or tolerance. Immunol. Rev. 182: 164-179. (Pubitemid 33070216)
23. Huurman, V A., J. H. Velthuis, R. Hilbrands, T. I. Tree, P. Gillard, P. M. van der Meer-Prins, G. Duinkerken, G. G. Pinkse, B. Keymeulen, D. L. Roelen, et al. 2009. Allograft-specific cytokine profiles associate with clinical outcome after islet cell transplantation. Am. J. Transplant. 9: 382-388.
24. Lawson, J. M., J. Tremble, C. Dayan, H. Beyan, R. D. Leslie, M. Peakman, and T. I. Tree. 2008. Increased resistance to CD4+CD25hi regulatory T cell-mediated suppression in patients with type 1 diabetes. Clin. Exp. Immunol. 154: 353-359.
25. Schneider, A., M. Rieck, S. Sanda, C. Pihoker, C. Greenbaum, and J. H. Buckner. 2008. The effector T cells of diabetic subjects are resistant to regulation via CD4+ FOXP3+ regulatory T cells. J. Immunol. 181: 7350-7355.
26. Moxham, V. F., J. Karegli, R. E. Phillips, K. L. Brown, T. T. Tapmeier, R. Hangartner, S. H. Sacks, and W. Wong. 2008. Homeostatic proliferation of lymphocytes results in augmented memory-like function and accelerated al-lograft rejection. J. Immunol. 180: 3910-3918.
27. Daikeler, T., and A. Tyndall. 2007. Autoimmunity following haematopoietic stem-cell transplantation. Best Pract. Res. Clin. Haematol. 20: 349-360. (Pubitemid 46585970)
28. Trenado, A., F. Charlotte, S. Fisson, M. Yagello, D. Klatzmann, B. L. Salomon, and J. L. Cohen. 2003. Recipient-type specific CD4+CD25+ regulatory T cells favor immune reconstitution and control graft-versus-host disease while maintaining graft-versus-leukemia. J. Clin. Invest. 112: 1688-1696. (Pubitemid 38063726)
29. Bloom, D. D., Z. Chang, J. H. Fechner, W. Dar, S. P. Polster, J. Pascual, L. A. Turka, and S. J. Knechtle. 2008. CD4+ CD25+ FOXP3+ regulatory T cells increase de novo in kidney transplant patients after immunodepletion with Campath-1H. Am. J. Transplant. 8: 793-802. (Pubitemid 351347746)
30. Monti, P., M. Scirpoli, P. Maffi, N. Ghidoli, F. De Taddeo, F. Bertuzzi, L. Piemonti, M. Falcone, A. Secchi, and E. Bonifacio. 2008. Islet transplantation in patients with autoimmune diabetes induces homeostatic cytokines that expand autoreactive memory T cells. J. Clin. Invest. 118: 1806-1814. (Pubitemid 351632383)
31. Hire, K., D. K. Ngo, K. M. Stewart-Maynard, B. Hering, and P. Bansal-Pakala. 2012. FoxP3+, and not CD25+, T cells increase post-transplant in islet allo-transplant recipients following anti-CD25+ rATG immunotherapy. Cell. Immunol. 274: 83-88.
32. Yagi, H., A. Soto-Gutierrez, B. Parekkadan, Y. Kitagawa, R. G. Tompkins, N. Kobayashi, and M. L. Yarmush. 2010. Mesenchymal stem cells: Mechanisms of immunomodulation and homing. Cell Transplant. 19: 667-679.
33. Parekkadan, B., and J. M. Milwid. 2010. Mesenchymal stem cells as therapeutics. Annu. Rev. Biomed. Eng. 12: 87-117.
34. Roobrouck, V. D., C. Clavel, S. A. Jacobs, F. Ulloa-Montoya, S. Crippa, A. Sohni, S. J. Roberts, F. P. Luyten, S. W. Van Gool, M. Sampaolesi, et al. 2011. Differentiation potential of human postnatal mesenchymal stem cells, meso-angioblasts, and multipotent adult progenitor cells reflected in their transcriptome and partially influenced by the culture conditions. Stem Cells 29: 871-882.
35. Roobrouck, V. D., K. Vanuytsel, and C. M. Verfaillie. 2011. Concise review: culture mediated changes in fate and/or potency of stem cells. Stem Cells 29: 583-589.
36. Highfill, S. L., R. M. Kelly, M. J. O'Shaughnessy, Q. Zhou, L. Xia, A. Panoskaltsis-Mortari, P. A. Taylor, J. Tolar, and B. R. Blazar. 2009. Multipotent adult progenitor cells can suppress graft-versus-host disease via prosta-glandin E2 synthesis and only if localized to sites of allopriming. Blood 114: 693-701.
37. Mora-Lee, S., M. S. Sirerol-Piquer, M. Gutiérrez-Pérez, U. Gomez-Pinedo, V. D. Roobrouck, T. López, M. Casado-Nieto, G. Abizanda, M. T. Rabena, C. Verfaille, et al. 2012. Therapeutic effects of hMAPC and hMSC transplantation after stroke in mice. PLoS ONE 7: e43683.
38. Kovacsovics-Bankowski, M., P. R. Streeter, K. A. Mauch, M. R. Frey, A. Raber, W. van't Hof, R. Deans, and R. T. Maziarz. 2009. Clinical scale expanded adult pluripotent stem cells prevent graft-versus-host disease. Cell. Immunol. 255: 55-60.
39. Meisel, R., A. Zibert, M. Laryea, U. Göbel, W. Däubener, and D. Dilloo. 2004. Human bone marrow stromal cells inhibit allogeneic T-cell responses by indo-leamine 2, 3-dioxygenase-mediated tryptophan degradation. Blood 103: 4619-4621. (Pubitemid 38745993)
40. Jacobs, S. A., J. Pinxteren, V. D. Roobrouck, A. Luyckx, W. Van't Hof, R. Deans, C. M. Verfaillie, M. Waer, A. D. Billiau, and S. W. Van Gool. 2012. Human multipotent adult progenitor cells are non-immunogenic and exert potent immunomodulatory effects on alloreactive T cell responses. Cell Transplant. DOI:10.3727/096368912X657369.
41. English, K. 2013. Mechanisms of mesenchymal stromal cell immunomodulation. Immunol. Cell Biol. 91: 19-26.
42. Guo, Z., C. Zheng, Z. Chen, D. Gu, W. Du, J. Ge, Z. Han, and R. Yang. 2009. Fetal BM-derived mesenchymal stem cells promote the expansion of human Th17 cells, but inhibit the production of Th1 cells. Eur. J. Immunol. 39: 2840-2849.
43. Duffy, M. M., J. Pindjakova, S. A. Hanley, C. McCarthy, G. A. Weidhofer, E. M. Sweeney, K. English, G. Shaw, J. M. Murphy, F. P. Barry, et al. 2011. Mesenchymal stem cell inhibition of T-helper 17 cell-differentiation is triggered by cell-cell contact and mediated by prostaglandin E2 via the EP4 receptor. Eur. J. Immunol. 41: 2840-2851.
44. Ghannam, S., J. Pène, G. Torcy-Moquet, C. Jorgensen, and H. Yssel. 2010. Mesenchymal stem cells inhibit human Th17 cell differentiation and function and induce a T regulatory cell phenotype. J. Immunol. 185: 302-312.
45. Tso, G. H., H. K. Law, W. Tu, G. C. Chan, and Y. L. Lau. 2010. Phagocytosis of apoptotic cells modulates mesenchymal stem cells osteogenic differentiation to enhance IL-17 and RANKL expression on CD4+ T cells. Stem Cells 28: 939-954.
46. Tatara, R., K. Ozaki, Y. Kikuchi, K. Hatanaka, I. Oh, A. Meguro, H. Matsu, K. Sato, and K. Ozawa. 2011. Mesenchymal stromal cells inhibit Th17 but not regulatory T-cell differentiation. Cytotherapy 13: 686-694.
47. Carrión, F., E. Nova, P. Luz, F. Apablaza, and F. Figueroa. 2011. Opposing effect of mesenchymal stem cells on Th1 and Th17 cell polarization according to the state of CD4+ T cell activation. Immunol. Lett. 135: 10-16.
48. Darlington, P. J., M. N. Boivin, C. Renoux, M. François, J. Galipeau, M. S. Freedman, H. L. Atkins, J. A. Cohen, L. Solchaga, and A. Bar-Or. 2010. Reciprocal Th1 and Th17 regulation by mesenchymal stem cells: Implication for multiple sclerosis. Ann. Neurol. 68: 540-545.
49. Zanone, M. M., E. Favaro, I. Miceli, G. Grassi, E. Camussi, C. Caorsi, A. Amoroso, M. Giovarelli, P. C. Perin, and G. Camussi. 2010. Human mes-enchymal stem cells modulate cellular immune response to islet antigen glutamic acid decarboxylase in type 1 diabetes. J. Clin. Endocrinol. Metab. 95: 3788-3797.
50. Bocelli-Tyndall, C., L. Bracci, S. Schaeren, C. Feder-Mengus, A. Barbero, A. Tyndall, and G. C. Spagnoli. 2009. Human bone marrow mesenchymal stem cells and chondrocytes promote and/or suppress the in vitro proliferation of lymphocytes stimulated by interleukins 2, 7 and 15. Ann. Rheum. Dis. 68: 1352-1359.
51. Di Nicola, M., C. Carlo-Stella, M. Magni, M. Milanesi, P. D. Longoni, P. Matteucci, S. Grisanti, and A. M. Gianni. 2002. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 99: 3838-3843. (Pubitemid 34534559)
52. Krampera, M., S. Glennie, J. Dyson, D. Scott, R. Laylor, E. Simpson, and F. Dazzi. 2003. Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood 101: 3722-3729. (Pubitemid 36857965)
53. Glennie, S., I. Soeiro, P. J. Dyson, E. W. Lam, and F. Dazzi. 2005. Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells. Blood 105: 2821-2827. (Pubitemid 40446275)
54. Munn, D. H., M. D. Sharma, B. Baban, H. P. Harding, Y. Zhang, D. Ron, and A. L. Mellor. 2005. GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2, 3-dioxygenase. Immunity 22: 633-642. (Pubitemid 40719198)
55. Busch, S. A., S. T. J. van Crutchen, R. J. Deans, and A. E. Ting. 2011. Mes-enchymal Stromal Cells as a Therapeutic Strategy to Support Islet Transplantation in Type 1 Diabetes Mellitus. Cell Medicine 2: 43-53.